Is there any genetic predisposition of MMP-9 gene C1562T and MTHFR gene C677T polymorphisms with essential hypertension?

Cytotechnology

Volumn 67, Issue 1, 2015, Pages 115-122

  Bayramoglu, Aysegul ^a   Urhan Kucuk, Meral ^b   Guler, Halıl Ibrahim ^a   Abaci, Okay ^c   Kucukkaya, Yunus ^d   Colak, Ertugrul ^e  

^a ARTVIN CORUH UNIVERSITY   (Turkey)

^b MUSTAFA KEMAL UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d ADIYAMAN UNIVERSITY   (Turkey)

^e ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Essential hypertension; MMP 9; MMP 9 C1562T polymorphism; MTHFR; MTHFR C677T polymorphism

Indexed keywords

EID: 84887582242     PISSN: 09209069     EISSN: 15730778     Source Type: Journal    
DOI: 10.1007/s10616-013-9665-0     Document Type: Article

References (44)

1. Apakkan Aksun AS, Ozmen D, Bayındır O (2001) Metalloproteınases, theır ınhıbıtors and related physıologıcal and pathologıcal condıtıons. T Klin J Med Sci 21:332–342
2. Bayramoglu A, Gunes HV, Metintas M, Degirmenci I, Mutlu F, Alatas F (2009) The association of MMP-9 enzyme activity, MMP-9 C1562T polymorphism, and MMP-2 and -9 and TIMP-1, -2, -3, and -4 gene expression in lung cancer. Genet Test Mol Biomarks 13:671–678
3. Bayramoglu A, Gunes HV, Metintas M, Degirmenci I, Akın A, Kurt H (2010) Is a single nucleotide polymorphism a risk factor for lung cancer in the matrix metalloproteinase-2 promoter? Mol Biol Rep 38:1469–1474
4. Bayramoglu A, Gunes HV, Metintas M, Degirmenci I, Akın A, Kurt H (2011) Is a single nucleotide polymorphism a risk factor for lung cancer in the matrix metalloproteinase-2 promoter? Mol Biol Rep 38:1469–1474
5. Bayramoglu A, Kucuk Urhan M, Ercan S, Abacı O, Guler HI, Kucukkaya Y, Korkmaz MC (2012) Hypertension and matrix metalloproteinase-9 enzyme activity. J Selcuk Univ Natur Appl Sci 3:60–68
6. Berg G, Miksztowicz V, Schreier L (2011) Metalloproteinases in metabolic syndrome. Clin Chim Acta 412:1731–1739
7. Bova I, Chapman J, Sylantiev C, Korczyn AD, Bornstein NM (1999) The A677C methylenetetrahydrofolate reductase gene polymorphism and carotid atherosclerosis. Stroke 30:2180–2182
8. Chintala SK, Tonn JC, Rao JS (1999) Matrix metalloproteinases and their biological function in human gliomas. Int J Dev Neurosci 17:495–502
9. Corbel M, Boichot E, Langente V (2000) Role of gelatinases MMP-2 and MMP-9 in tissue remodeling following acute lung injury. Braz J Med Biol Res 33:749–754
10. Daly SF, Molloy AM, Mills JL, Lee YJ, Conley M, Kirke PN, Weir DG, Scott JM (1999) The influence of 5, 10 methylenetetrahydrofolate reductase genotypes on enzyme activity in placental tissue. Brit J Obstet Gynaecol 106:1214–1218
11. De Souza AP, Trevillato RM, Scarel-Caminaga RM, De Brito RB, Barros SP, Line SRP (2005) Analysis of the MMP-9 (C1562T) And TIMP-2 (G418C) gene promotör polymorphisims in patients with chronic periodontitis. J Clin Periodontol 32:207–211
12. Derosa G, D’Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, Cicero AF (2006) Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 13:227–231
13. Dikmen M, Gülel B, Günes HV, Gücüyener D, Degırmencı I, Ozdemir G, Basaran A (2004) The effect of MTHFR gene polymorphisms on the homocysteine level, a risk factor, in acute stroke patients. Kocatepe Med J 5:55–61
14. Fontana V, Silva PS, Belo VA, Antonio RC, Ceron CS, Biagi C, Gerlach RF, Tanus-Santos JE (2011) Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target. Basic Clin Pharmacol Toxicol 109:130–137
15. Friese RS, Rao F, Khandrika S, Thomas B, Ziegler MG, Schmid-Schönbein GW, O’Connor DT (2009) Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clin Exp Hypertens 31:521–533
16. Gai X, Lan X, Luo Z, Wang F, Liang Y, Zhang H, Zhang W, Hou J, Huang M (2009) Association of MMP-9 gene polymorphisms with atrial fibrillation in hypertensive heart disease patients. Clin Chim Acta 408:105–109
17. Goyette P, Rozen R (2000) The thermolabile variant 677CT can further reduce activity when expressed in CIS with severe mutations for human methylenetetrahydrofolate reductase. Hum Mutat 16:132–138
18. Gunes HV, Ata N, Degırmencı I, Basaran A, Tımuralp B, Dıkmen M, Ustuner C, Kudaıberdıeva G (2004) Frequency of angiotensin-converting enzyme gene polymorphism in Turkish hypertensive patients. Int J Clin Pract 58:838–843
19. Heux S, Morın F, Lea RA, Ovcaric M, Tajouri L, Griffiths LR (2004) The methylentetrahydrofolate reductase gene variant (C677T) as a risk factor for essential hypertension in Caucasians. Hypertens Res 27:663–667
20. Homberger G, Linnebank M, Winter C, Willenbring H, Marquardt T, Harms E, Koch HG (2000) Genomic structure and transcript variants of the human methylenetetrahydrofolate reductase gene. Eur J Hum Genet 8:725–729
21. Huhtala P, Chows LT, Tryggvason K (1990) Structure of the human type IV collagenase gene. J Biol Chem 265:11077–11082
22. Hulyam K, Aysegul B, Veysi GH, Demet O, Irfan D, Ertugrul C, Didem CT, Banu B, Miris D (2013) Frequency of angiotensin II type 1 receptor gene polymorphism in Turkish acute stroke patients. J Cell Mol Med 17:475–481
23. Humphrey D (2008) Mechanisms of arterial remodelling in hypertension: coupled roles of wall shear an intramural stress. Hypertension 52:195–200
24. Ilhan N, Kucuksu M, Kaman D, Ilhan N, Ozbay Y (2008) The 677 C/T MTHFR polymorphism is associated with essential hypertension, coronary artery disease, and higher homocysteine levels. Arch Med Res 39:125–130
25. Kang S, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N (1991) Thermolabile methylenetetrahydrofolate reductase: an ınherited risk factor for coronary artery disease. J Hum Genet 48:536–545
26. Kleiner DE, Stetler-Stevenson WG (1999) Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43:42–51
27. Koo HS, Lee HL, Hong YM (2008) Methylenetetrahydrofolate reductase TT genotype as a predictor of cardiovascular risk in hypertensive adolescents. Pediatr Cardiol 29:136–141
28. Kosmas IP, Tatsioni A, Ioannidis JPA (2004) Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 22:1655–1662
29. Lacchini R, Jacob-Ferreira ALB, Luizon MR, Coeli FB, Izidoro-Toledo TC, Gasparini S, Ferreira-Sae MC, Schreiber R, Nadruz W, Tanus-Santos JE (2010) Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. Clin Chim Acta 411:1940–1944
30. Lee H, Choi J, Ha K, Yang DH, Chang SK, Hong SY (1999) Influence of 5, 10- methylenetetrahydrofolate reductase gene polymorphism on plasma homocysteine concentration in patients with end-stage renal disease. Am J Kidney Dis 34:259–263
31. Lifton RP, Gharavi AG, Geller DS (2001) Molecular mechanisms of human hypertension. Cell 104:545–556
32. Markan S, Sachdeva M, Sehrawat BS, Kumari S, Jain S, Khullar M (2007) MTHFR 677 CT/MTHFR 1298 CC genotypes are associated with increased risk of hypertension in Indians. Mol Cell Biochem 302:125–131
33. Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF, Tanus-Santos JE (2006) Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 47:117–122
34. Nguyen M, Aekell J, Jackson C (2001) Human endotelhial gelatinases and angiogenesis. Int J Biochem Cell Biol 33:960–970
35. O’Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer EJ, Myers RH, Levy D (1998) Evidence for association and genetic linkage of the angiotensin converting enzyme locus with hypertansion and blood pressure in men but women in the framingham heart study. Circulation 97:1766–1772
36. Palei ACT, Sandrim VC, Duarte G, Cavalli RC, Gerlach RF, Tanus-Santos JE (2010) Matrix metalloproteinase (MMP)-9 genotypes and haplotypes in preeclampsia and gestational hypertension. Clin Chim Acta 411:874–877
37. Palei ACT, Sandrim VC, Amaral LM, Machado JSR, Cavalli RC, Lacchini R, Duarte G, Tanus-Santos JE (2012) Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J 12:489–498
38. Qian X, Lu Z, Tan M, Liu H, Lu D (2007) A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension. Eur J Hum Genet 15:1239–1245
39. Rosenblatt DS (2001) Methylenetetrahydrofolate reductase. Clin Invest Med 24:56–59
40. Schmitz C, Lindpainter K, Verhoef P, Gaziano JM, Buring J (1996) Geneticpolymorphism of methylenetetrahydrofolate reductase and myocardial infarction. Circulation 94:1812–1814
41. Schneider JA, Rees DC, Liu YT, Clegg JB (1998) Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 62:1258–1260
42. Song WH, Dang AM, Zhu JM, Lü NQ, Liu GZ, Hui RT (2006) MMP-9 gene -1562C/T polymorphism in aortic dissection in Chinese hypertensive patients. Zhonghua Nei Ke Za Zhi 45:376–378
43. Stern LL, Bagley PJ, Rosenberg IH, Selhub J (2000) Conversion of 5-formyltetrahydrofolic acid is unimpaired in folate- adequate persons homozygous for the C677T mutation in the methylenetetrahydrofolate reductase gene. J Nutr 130:2238–2242
44. Zhou S, Feely J, Spiers JP, Mahmud A (2007) Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension MMP-9 gene and arterial stiffness in hypertension. J Hum Hypertens 21:861–867